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a b s t r a c t
Interferon-induced transmembrane (IFITM) proteins inhibit the infection of a wide range of viruses
including human immunodeﬁciency virus type 1 (HIV-1). At present, little is known about how viruses
overcome IFITM restriction. In this study, we have utilized HIV-1 as a model and selected IFITM1-
resistant viruses after multiple passages of HIV-1 in IFITM1-expressing SupT1 cells. Sequencing the entire
viral genome revealed several mutations in the vpu and envelope genes, among which mutations Vpu34
and EnvG367E together enable efﬁcient HIV-1 replication in IFITM1-expressing cells. Vpu34 introduces a
stop codon at amino acid position 35 of Vpu, whereas EnvG367E changes the G367 residue at the CD4-
binding site of gp120. These two mutations do not appear to overcome the downregulation of viral p24
expression caused by IFITM1, but rather enhance HIV-1 replication by promoting cell-to-cell virus
transmission. Altogether, our data demonstrate that HIV-1 can mutate to evade IFITM1 restriction by
increasing cell-to-cell transmission.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Interferon (IFN) inhibits virus infection through inducing the
expression of hundreds of cellular genes collectively known as
interferon-stimulated genes (ISGs) (Sadler and Williams, 2008).
The antiviral functions of some of these ISGs have been well
characterized. Examples include the RNase L and OAS proteins,
protein kinase R (PKR), myxovirus-resistance (Mx) proteins, ISG15,
APOBEC3G (apolipoprotein B mRNA-editing, enzyme-catalytic,
polypeptide-like 3G), TRIM5α (Tripartite motif-containing protein
5α), tetherin, SAMHD1 (SAM domain and HD domain-containing
protein 1) and Schlafen 11 (Hrecka et al., 2011; Laguette et al.,
2011; Li et al., 2012; Neil et al., 2008; Sadler and Williams, 2008;
Stremlau et al., 2004). A recent addition to this list is the
interferon-induced transmembrane (IFITM) proteins which inhibit
a number of highly pathogenic human viruses (Brass et al., 2009;
Huang et al., 2011; Jiang et al., 2010; Lu et al., 2011; Schoggins
et al., 2011; Weidner et al., 2010). IFITM proteins are distinct from
all other ISGs in that they inhibit viral entry, particularly the
step of membrane fusion (Brass et al., 2009; Feeley et al., 2011;
Huang et al., 2011; Li et al., 2013; Lu et al., 2011) (reviewed in
(Diamond and Farzan, 2013; Perreira et al., 2013)).
Humans have IFITM1, 2, 3, 5 and 10, all of which are located on
chromosome 11 (Hickford et al., 2012). IFITM1, 2, 3 and 5 are
clustered in a 26.5 kb region, whereas IFITM10 is located 1.4 Mb
apart. IFITM5 is also called bone-restricted IFITM-like (Bril) protein
due to its strict expression in osteoblasts and its role in bone
mineralization and maturation (Hanagata et al., 2010; Moffatt
et al., 2008). The function of IFITM10 is unknown, but it is highly
conserved in different species (Hickford et al., 2012). IFITM1, 2 and
3 have been shown to promote anti-proliferation, homotypic cell
adhesion, and apoptosis (Brem et al., 2003; Deblandre et al., 1995;
Evans et al., 1993, 1990). They are also overexpressed in some
tumor cells, such as human colorectal tumors, suggesting a
possible role in oncogenesis (Andreu et al., 2006; Siegrist et al.,
2011). In addition to their ubiquitous expression in different
tissues (Seo et al., 2010; Yamashita et al., 2000), IFITM1, 2 and
3 also respond to the stimulation by interferon (Lewin et al., 1991),
supporting their roles in host antiviral defense. Indeed, IFITM1,
2 and 3 have been reported to inhibit the infections by inﬂuenza A
virus (IAV), ﬂavivirus (West Nile virus, Dengue virus, and Yellow
Fever virus), ﬁlovirus (Ebola virus and Marburg virus), SARS
coronavirus, vesicular stomatitis virus (VSV), hepatitis C virus
(HCV), reovirus, Rift Valley fever virus, as well as human immuno-
deﬁciency virus type 1 (HIV-1) (Anafu et al., 2013; Brass et al., 2009;
Feeley et al., 2011; Jiang et al., 2010; Lu et al., 2011; Mudhasani
et al., 2013; Raychoudhuri et al., 2011; Schoggins et al., 2011;
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Weidner et al., 2010). In addition to this broad antiviral activity,
knockout of iﬁtm3 in mice or IFITM3 deﬁciency in humans renders
the hosts highly vulnerable to IAV infection (Bailey et al., 2012;
Everitt et al., 2012; Wakim et al., 2013), highlighting the importance
of IFITM proteins in host antiviral defense in vivo.
Human IFITM1, 2 and 3 are of 125, 132 and 133 amino acids in
length, respectively. They are predicted to have two transmem-
brane domains (Siegrist et al., 2011). Results of cell-surface
immunostaining and ﬂow cytometry experiments suggest that
their amino- and carboxy-termini project toward the extracellular
space or luminal compartments (Brass et al., 2009; Weidner et al.,
2010). However, recent evidence also supports the cytoplasmic
localization of the N-terminus (Bailey et al., 2013; Yount et al.,
2012). In addition to the plasma membrane, IFITM proteins are
also observed in the endoplasmic reticulum (ER) and endosomes
(Alber and Staeheli, 1996; Brass et al., 2009; Feeley et al., 2011; Jia
et al., 2012; Lu et al., 2011; Yang et al., 2007; Yount et al., 2010;
Zucchi et al., 2004). The localization of IFITM3 in late endosomes is
important for inhibiting IAV infection, because ectopic expression
of IFITM3, or its induced expression by interferon, causes expan-
sion of late endosomes and lysosomes and results in the seques-
tration of endocytosed IAV particles in these acidic membrane
compartments (Feeley et al., 2011; Huang et al., 2011). By taking
advantage of lipid analogs and ﬂuorescence labeling, we recently
showed that oleic acid (OA), but not chlorpromazine (CPZ), rescues
the inhibitory effect of IFITMs on cell-to-cell fusion induced by
Jaagsiekte sheep retrovirus (JSRV) Env and IAV hemagglutinin
(HA), indicating that IFITM proteins interfere with the hemifusion
stage of virus entry, possibly by changing membrane ﬂuidity and
curvature (Li et al., 2013). This conclusion is further strengthened
Fig. 1. Identiﬁcation of escape mutations. (A) Replication of wild type HIV-1 and the escape viruses named HIV-1(R) in IFITM1-expressing SupT1 cells. The same amounts of
viruses were used to infect SupT1 cells expressing IFITM1 with induction by doxycycline. Amounts of viruses in the supernatants were determined by measuring the viral
reverse transcriptase activity. The expression of IFITM1-Flag in SupT1 cells was examined by Western blotting with doxycycline (Dox) induction. (B) Illustration of the escape
mutations in HIV-1 genome. Seven viral DNA clones were sequenced. The frequency of each mutation in seven clones is shown. (C) Vpu28 and Vpu34 mutations cause
premature termination of Vpu translation. Part of the DNA sequences and amino acid sequences of the wild type and mutated Vpu are shown. The Vpu fragments of the
Vpu28 and Vpu34 mutants are illustrated. (D) Mutations EnvR311K and EnvG367E are located in the V3 and C3 regions of envelope protein, respectively. The g7178a
mutation does not cause amino acid change. Part of the DNA sequences and amino acid sequences of the EnvR311K and EnvG367E mutations are presented. Locations of
these two mutations in the gp120 structural model are shown. The structural models were generated using the I-TASSER server for protein 3D structure prediction (Zhang,
2008).
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by the fact that IFITM proteins increase lipid order of membranes
(Li et al., 2013). This latter property of IFITM proteins is at least
partially attributed to their interaction with VAPA (vesicle-mem-
brane-protein-associated protein A) and consequent disturbance
of cholesterol homeostasis (Amini-Bavil-Olyaee et al., 2013).
Viruses often evolve mechanisms to evade or antagonize host
restrictions (Malim and Bieniasz, 2012), and this strategy should
also be operative for the IFITM proteins. Indeed, HCV infection
increases the expression of miR-130a that targets the 30 untrans-
lated region of IFITM1 mRNA and thus diminishes IFITM1 expres-
sion (Bhanja Chowdhury et al., 2012). Additionally, arenaviruses,
which require low pH for entry, are refractory to IFITM restriction
(Brass et al., 2009), although the underlying mechanism still
remains unclear. In order to better understand the viral evasion
of IFITM restriction, we investigated whether HIV-1 can develop
resistance to IFITM1 in CD4þ SupT1 cells. The results showed that
long-term culture led to the emergence of IFITM1-resistant HIV-1
mutants, and the escape mutations were mapped to the viral Vpu
and Env proteins.
Results
HIV-1 mutates to escape from the inhibition by IFITM1 in SupT1 cells
We previously reported that IFITM1, 2 and 3 suppressed HIV-1
replication in SupT1 cells, with IFITM1 exhibiting the greatest
inhibition (Lu et al., 2011). In order to investigate whether HIV-1 is
able to develop resistance to IFITM restriction, we grew HIV-1 in
IFITM1-expressing SupT1 cells and observed that the virus gradu-
ally became refractory to IFITM1 inhibition and replicated to high
levels (Fig. 1A). As a control, we also grew HIV-1 in SupT1 cells
without ectopic expression of IFITM1 for the same time interval.
We then sequenced the entire genomes of these two virus
populations. Five mutations were identiﬁed only in IFITM1-
resistant viruses, not in those that had replicated in the control
SupT1 cells (Fig. 1B). Two mutations are located in Vpu, namely
Vpu28 and Vpu34, respectively. Vpu28 was seen in two out of the
seven sequenced viral DNA clones, Vpu34 in ﬁve clones, indicating
that the virus either carried the Vpu28 or the Vpu34 mutation.
Both mutations created a stop-codon, resulting in the premature
termination of Vpu translation (Fig. 1C). The other three mutations
were found in the Env coding region (Fig. 1B). EnvR311K resides in
the variable loop 3 (V3), which is critical for co-receptor-binding
(Fig. 1D). EnvG367E is in the CD4-binding site in constant region 3
(C3) (Fig. 1D). The g7178a mutation does not cause any amino acid
change in envelope, nor in the Rev or Tat proteins. This mutation
was found in ﬁve out of the seven sequenced DNA clones. These
data suggest that HIV-1 is able to escape from IFITM1 inhibition by
mutating its Vpu and Env proteins.
The Vpu34 and EnvG367E mutations rescue HIV-1 replication
in IFITM1-expressing SupT1 cells
We next asked which of these ﬁve mutations are sufﬁcient to
rescue the IFITM1 inhibition of HIV-1. Since Vpu28 and Vpu34
mutations both resulted in truncation of Vpu, and Vpu34 was seen
in ﬁve out of seven viral DNA clones, we chose to further
characterize Vpu34 by performing the following experiments.
We inserted Vpu34, EnvR311K, EnvG367E and g7178a into the
HIV-1 proviral DNA either individually or in different combina-
tions, and generated 11 mutated HIV-1 DNA clones (Table 1). We
then transfected these viral DNA clones into HEK293T cells to
produce viruses, and used viruses of the same viral p24 amounts
to infect SupT1 cells that were induced with doxycycline to
express IFITM1. Infection experiments were also performed
without doxycycline as the control for the IFITM1-negative con-
dition. In the absence of IFITM1 expression, HIV-1(Mut4) (contain-
ing Vpu34, EnvR311K, EnvG367E and g7178a mutations), Vpu34/
EnvG367E, and Vpu34/EnvR311K/G367E grew slightly faster than
the wild type virus and other viruses (Fig. 2). With IFITM1
expression, viruses HIV-1(Mut4), Vpu34/EnvR311K/G367E, and
Vpu34/EnvG367E exhibited much robust replication, in strong
comparison to the wild type and other mutants which were
inhibited by IFITM1 (Fig. 2). We thus conclude that the Vpu34
and EnvG367E mutations together are sufﬁcient to overcome
IFITM1 inhibition, and that EnvR311K and g7178a do not play an
important role.
The Vpu34 mutation allows the expression of the ﬁrst 34 amino
acids of Vpu (Fig. 1C). In order to test whether this truncated form
of Vpu contributes to the rescue of HIV-1, we mutated the
translation start codon AUG of Vpu to ACG in order to completely
eliminate the Vpu expression. We inserted this Vpu() mutation
into the wild type and the mutated HIV-1 DNA, and generated
mutants HIV-1/Vpu(), HIV-1(Mut4)/Vpu(), Vpu34/EnvG367E/
Vpu(), and Vpu34/EnvR311K/G367E/Vpu(). We observed that,
in contrast to the complete inhibition of HIV-1/Vpu() by IFITM1,
the other three viruses replicated efﬁciently (Fig. 3A). We further
showed that the Vpu34 mutation was sufﬁcient to block the
downregulation of cell surface CD4 by HIV-1 (Fig. 3B). Therefore,
the loss of Vpu expression, but not the expression of the ﬁrst 34
amino acids of Vpu, enables the virus to escape IFITM1 inhibition.
The Vpu34 and EnvG367E mutations do not rescue the defect
in HIV-1 p24 expression caused by IFITM1
We next performed short-term infection to investigate the
rescue mechanism conferred by Vpu34 and EnvG367E. We have
previously shown that IFITM1 decreases the expression of HIV-1
p24 (Lu et al., 2011), an observation that is further supported by
the study of Chutiwitoonchai et al. (2013). To test whether the
Vpu34 and EnvG367E mutations can overcome this defect, SupT1
cells were infected with the same amounts of wild type and
mutated HIV-1 particles, and viral Gag/p24 expression was mea-
sured by staining cells with FITC-conjugated anti-p24 antibody. In
the absence of IFITM1 expression, viruses HIV-1(Mut4), Vpu34/
EnvG367E and EnvG367E generated 10-fold fewer p24-positive
SupT1 cells than the wild type virus and the Vpu34 mutant
(Fig. 4A). This observation was conﬁrmed by the results of Western
blots measuring cell-associated HIV-1 Gag and p24 (Fig. 4B, 200 ng
p24 virus infection). This deﬁciency was likely a result of the
impaired virus entry, since results of HIV-1 virion fusion experi-
ments showed that the HIV-1(Mut4), Vpu34/EnvG367E and
EnvG367E mutants were more than 10 fold less efﬁcient in
Table 1
Mutations in each HIV-1 mutant.
HIV-1 mutants Mutations
Vpu34 R311K G367E g7178a
HIV-1(Mut4) √ √ √ √
Vpu34 √
EnvR311K √
EnvG367E √
Envg7178a √
EnvR311KG367E √ √
Vpu34/EnvR311K √ √
Vpu34/EnvG367E √ √
Vpu34/Envg7178a √ √
EnvR311K/G367E/g7178a √ √ √
Vpu34/EnvR311K/G367E √ √ √
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Fig. 2. Mutations of Vpu34 and EnvG367E rescue HIV-1 replication in IFITM1-expressing SupT1 cells. The mutations Vpu34, EnvR311K, EnvG367E and g7178a were inserted
into HIV-1 DNA either individually or in different combinations. The HIV-1(Mut4) virus contains all four mutations. These viruses were used to infect SupT1 cells with or
without IFITM1 induction by doxycycline. Viral replication was determined by measuring levels of viral reverse transcriptase activity in culture supernatants. Results shown
represent three independent infection experiments.
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entering cells than the wild type and the Vp34 mutant (Fig. 4C).
Given that HIV-1(Mut4), Vpu34/EnvG367E and EnvG367E all bear
the EnvG367E mutation, we suspected that this envelope protein
mutation likely have dramatically diminished HIV-1 infectivity.
Supporting this speculation, we found that this defect in infection
was fully corrected when the wild type and mutated viruses
carried the VSV G protein that is not affected by IFITM1
(Weidner et al., 2010) (Fig. 4D). Interestingly, when IFITM1 was
induced to express, both the wild type and the mutated viruses
either bearing HIV-1 envelope or VSV G protein, still gave 50%
fewer p24-positive SupT1 cells (Fig. 4A and D). This decrease is
more pronounced when levels of cell-associated HIV-1 p24 were
measured by Western blotting, and this decrease persisted until
later time points of infection such as day 4 and day 8 (Fig. 4B).
In addition, the results of Western blots showed decreased ratio
of p24 to pr55 in IFITM1-expressing cells (Fig. 4E), which indicates
a defect in Gag processing. These defects were further reﬂected
by a similar reduction in virus particles that were released into
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Fig. 3. Deleting Vpu facilitates HIV-1 to escape IFITM1 inhibition. (A) Abolishing Vpu expression does not affect the ability of Vpu34 mutation to rescue HIV-1 replication in
IFITM1-expressing SupT1 cells. The ﬁrst ATG of Vpu was changed to ACG, which is named Vpu(). This Vpu() mutation was inserted into viral DNA clones HIV-1(Mut4),
Vpu34/EnvG367E, and Vpu34/R311K/EnvG367E such that the expression of the ﬁrst 34 amino acids of Vpu in these viruses are eliminated. Virus replication in SupT1 cells,
with or without IFITM1 induction, was monitored by measuring levels of viral reverse transcriptase activity in culture supernatants. One representative result of three
independent infections is shown. (B) The Vpu34 mutation abolishes the ability of HIV-1 to downregulate cell surface CD4. The wild type HIV-1 and its mutants were used to
infect SupT1 cells. Forty hours after infection, cells were stained with PE-conjugated anti-CD4 antibody and FITC-conjugated anti-p24 antibody followed by ﬂow cytometry
analysis. Results shown represent three independent experiments.
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the supernatants (Fig. 4F). Therefore, the Vpu34 and EnvG367E
mutations are unable to repair the defect in viral p24 expression
caused by IFITM1, suggesting that they must have rescued HIV-1
replication in IFITM1-expressing SupT1 cells by a new mechanism.
The EnvG367E mutation impairs the usage of CD4 receptor
It is not surprising that the EnvG367E mutant is poorly
infectious because the EnvG367E mutation alters the conserved
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Fig. 4. The Vpu34 and EnvG367E mutations do not overcome Gag downregulation caused by IFITM1 in the short-term infection of HIV-1. (A) The wild type and mutant
viruses were used to infect SupT1 cells with or without IFITM1 induction. Forty hours after infection, the infected cells were stained with FITC-conjugated anti-p24 antibody
and scored by ﬂow cytometry. Results of three independent infections are summarized in the bar graph. The p values were calculated and the signiﬁcance is indicated by n
(o0.05) and nn (o0.01). (B) The infected cells were collected 2, 4 and 8 days after infection. Levels of HIV-1 Gag/p24 were examined in Western blots. (C) The cell entry
efﬁciency of wild type and mutant viruses were examined by Blam-Vpr virion fusion assay. The cleavage of CCF2/AM by Blam-Vpr was measured by ﬂow cytometry. Results
of three independent infections are summarized in the bar graph. (D) The wild type and mutant HIV-1 were pseudotyped with VSV G protein and used to infect SupT1 cells
with or without IFITM1 induction. Forty hours after infection, the infected cells were stained with FITC-conjugated anti-p24 antibody and scored by ﬂow cytometry. Results
of three independent infections are summarized in the bar graph. The p values were calculated and the signiﬁcance is indicated by n (o0.05) and nnn (o0.001). (E) Levels of
viral Gag/p24 expression in the infected cells were determined by Western blotting. The intensities of pr55 and p24 protein bands were determined with the Image J
software (NIH). The ratios of p24 to pr55 were calculated and shown below the Western blot. (F) Amounts of viruses in the culture supernatants were determined by
measuring viral reverse transcriptase activity. Virus amount that was produced by the wild type HIV-1 in the absence of doxycycline induction is arbitrarily set as 1. Results
shown are the averages of three independent infections. The p values were calculated and the signiﬁcance is indicated by nn (o0.01) and nnn (r0.001).
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G367 amino acid at the CD4-binding site (Fig. 1D). Such a mutation
would be expected to diminish the afﬁnity of envelope for CD4.
Indeed, we observed that as little as 0.1 mg/ml of soluble CD4
(sCD4(D1/D4)) was able to reduce the infection of wild type HIV-1
and the Vpu34 virus by 10-fold, as opposed to less than 30%
decrease for the EnvG367E, Vpu34/EnvG367E and HIV-1(Mut4)
viruses (Fig. 5A). We further tested the usage of CD4 receptor using
an antibody named VRC03 that recognizes the CD4-binding site on
gp120 (Wu et al., 2010; Zhou et al., 2010). Again, viruses HIV-1
(Mut4), EnvG367E and Vpu34/EnvG367E, which all carry the
EnvG367E mutation, exhibited greater resistance to VRC03 inhibi-
tion than the wild type virus (Fig. 5B).
We speculated that the diminished usage of CD4 by the
EnvG367E mutant may render the virus more sensitive to the cell
surface CD4 level. To test this possibility, we ﬁrst used the CD4
antibody SIM4 to block cell surface CD4 and then measured its
effect on HIV-1 infection. The results showed a much greater
inhibition of the Vpu34/EnvG367E and EnvG367E viruses as
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compared to the wild-type HIV-1 and the Vpu34 mutant (Fig. 5C).
Next, we used shRNA to knock down CD4 expression in SupT1
cells. Out of the four shRNA clones tested, one clone diminished
CD4 level by approximately 40% (Fig. 5D), the other three did not
signiﬁcantly affect CD4 expression (data not shown). This CD4-
knockdown SupT1 cell line was then infected by either the wild
type HIV-1 or the HIV-1(Mut4) virus. Compared to their replica-
tion in the control SupT1 cells, the growth of HIV-1(Mut4), but not
the wild type HIV-1, was delayed in the CD4-knockdown cells
(Fig. 5D). Results of Fig. 5E and F further showed that the Vpu34
and EnvG367E mutations did not affect the usage of CXCR4 as the
co-receptor, since all mutated viruses were as sensitive as the wild
type virus to the inhibition by the CXCR4 antagonist AMD3100
(Fig. 5E), and none was inhibited by the CCR5 antagonist maraviroc
(Fig. 5F). These results suggest a deﬁcient engagement of CD4 by
the mutated viral envelope EnvG367E.
The Vpu34 and EnvG367E mutations enhance HIV-1 cell-to-cell
transmission
It is intriguing that the Vpu34/EnvG367E virus particles were
10-fold less infectious than the wild type HIV-1 (Fig. 4), yet this
mutant replicates as efﬁciently as does the wild type virus in
SupT1 cells (Fig. 2). We also noted that, although infection of the
mutated viruses was initially impaired as shown by the results of
Western blotting at day 2 after infection, the HIV-1(Mut4) and
Vpu34/EnvG367E mutants produced similar levels of viral p24 as
compared to wild type HIV-1 at day 4 and day 8 after infection
(Fig. 4B). Given that cell-to-cell transmission of HIV-1 is known to
dominate virus spread over free-virus infection (Sattentau, 2008),
it is possible that the Vpu34/EnvG367E mutant compensates for its
reduced infectivity by enhancing cell-to-cell transmission. To test
this, we ﬁrst infected the donor SupT1 cells with the wild type or
mutated HIV-1 particles bearing the VSV-G protein, ensuring that
both wild type and mutated HIV-1 would generate similar num-
bers of infected donor cells. Forty hours after infection, donor cells
were mixed with target SupT1 cells that were labeled with a cell
tracker BMQC, and viral p24 was examined with FITC-conjugated
anti-p24 antibody. In order to distinguish cell-to-cell transmission
from free virus particles, we used trans-wells to separate donor
cells from target cells. As would be expected, few p24-positive
cells were detected in the trans-well infection (Fig. 6A), indicating
that free HIV-1 particles did not lead to signiﬁcant infection of
target cells. We then added HIV-1 fusion inhibitor T-20 into the
mixed cell population and did not observe signiﬁcant infection of
target cells (Fig. 6B), conﬁrming that the cell-to-cell virus trans-
mission shown in Fig. 6C is viral envelope-dependent. When the
control SupT1 cells (without IFITM1 expression) were used as the
target cells in the transmission assay, the HIV-1(Mut4) and Vpu34/
EnvG367E mutants were 3–4 fold more efﬁcient at cell-to-cell
transmission than the wild type virus or the Vpu34 and EnvG367E
mutants (Fig. 6C). We next used IFITM1-expressing SupT1 cells as
target cells, and observed that IFITM1 did not markedly affect HIV-
1 cell-to-cell transmission (Fig. 6D). Again, Vpu34 and EnvG367E
mutations together enhanced the transmission of viruses from
donor cells to IFITM1-expressing target cells (Fig. 6D). In order to
validate these data, we measured the amount of HIV-1 late cDNA
in the mixed of donor and target SupT1 cells at time 0 and 8 h after
mixing. The increases of HIV-1 late cDNA over a 8-h period of co-
culture are 4.6 and 3.7 folds for HIV-1(Mut4) and Vpu34/
EnvG367E, but are less than 2-fold for wild type HIV-1, Vpu34
and Env367E (Fig. 6F), which suggests a much higher cell-to-cell
transmission efﬁciency for HIV-1(Mut4) and Vpu34/EnvG367E.
Therefore, we conclude that the Vpu34 and EnvG367E mutations
rescue HIV-1 replication in IFITM1-expressing SupT1 cells through
promoting cell-to-cell virus transmission.
The effect of Vpu34 and EnvG367E on cell-to-cell transmission
is cell type-speciﬁc
Since the IFITM1-resistant mutations arose in SupT1 cells by
selection, we wished to examine the replication capacity of the
escape virus in other CD4þ T cell lines. Surprisingly, in contrast to
its higher-than wild type level replication in SupT1 cells, the HIV-1
(Mut4) mutant, which carried all escape mutations, was unable to
grow in CEM, Jurkat, and PM-1 cells (Fig. 7A), suggesting that this
escape mutant has adapted to SupT1 cells for efﬁcient replication.
We noticed that SupT1 cells express a relatively higher level of
CD4 than CEM, Jurkat and PM-1 cells (Fig. 7B), which may partially
underlie the much more efﬁcient replication of EnvG367E-
containing HIV-1 in SupT1 cells.
We next examined the cell-to-cell transmission efﬁciency of
HIV-1(Mut4) between CEM cells, and found that HIV-1(Mut4) was
unable to spread, consistent with its inability to grow in CEM cells
(Fig. 8A). This transmission deﬁciency was likely caused by the
EnvG367E mutation, because both EnvG367E and Vpu34/
EnvG367E were incompetent in cell-to-cell transmission, yet the
Vpu34 mutant spread more efﬁciently than the wild type virus
(Fig. 8A). To dissect whether this transmission deﬁciency is of
donor or target cell-effect, we performed additional cell-to-cell
transmission assays using SupT1 as donor and CEM cells as target
cells, or vice versa. The results showed that the HIV-1(Mut4),
EnvG367E, and Vpu34/EnvG367E mutants transmitted efﬁciently
only when SupT1 served as target cells (Fig. 8B–D), suggesting that
the target cell type determines the cell-to-cell transmission
efﬁciency of the EnvG367E-containing HIV-1 mutants. Altogether,
these data suggest that the Vpu34 and EnvG367E mutations were
selected to circumvent IFITM1 restriction in a cell type-speciﬁc
manner.
Discussion
In this study, we have identiﬁed two mutations Vpu34 and
EnvG367E that act together to rescue HIV-1 from IFITM1 restric-
tion. The Vpu34 mutation creates a translation stop codon at the
amino acid position 35 (Fig. 1C), resulting in the expression of
the ﬁrst 34 amino acids of Vpu that form the transmembrane
domain. We ruled out the involvement of this 34-amino-acid
Vpu fragment in antagonizing IFITM1, because eliminating the
full-length Vpu expression by mutating the translation start codon
AUG also enabled the EnvG367E mutation to rescue HIV-1 replica-
tion (Fig. 3). Together, our results indicate that the loss of Vpu and
a mutation in Env (EnvG367E) are both critical for HIV-1 to evade
IFITM1 restriction. We also detected the R311K mutation in the V3
loop of Env, but this mutation does not appear to contribute
signiﬁcantly to circumventing IFITM1. Nonetheless, mutating the
V3 loop may represent one way for the virus to counter different
inhibitory pressures. This scenario is supported by a recent study
showing that feline immunodeﬁciency virus is able to escape from
inhibition by a N-terminal fragment of TSG101 by acquiring a
K410N mutation in the V3 loop of its Env protein (Luttge et al.,
2013).
Vpu plays two major roles in HIV-1 replication; one is to down-
regulate the cell surface CD4, and another is to promote the virus
release by counteracting tetherin (Dube et al., 2010). Because the
Vpu34 mutant replicated almost as efﬁciently as the wild type
HIV-1 in SupT1 cells (Fig. 2), despite of its inability to down-
regulate the cell surface CD4 (Fig. 3B), Vpu is dispensable for HIV-1
to replicate in SupT1 cells. This could result from the lack of
endogenous tetherin expression in SupT1 (Rong et al., 2009),
which alleviates the need for Vpu to antagonize tetherin. It is
possible that, in the face of both tetherin and IFITM1, both of
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which can be induced by IFN, HIV-1 would have to overcome these
two restrictions by evolving pathways other than mutating
Vpu alone.
Our data show that Vpu34 mutation alone is insufﬁcient to
antagonize IFITM1, it needs to act together with the EnvG367E
mutation. The G367 amino acid in gp120 is highly conserved
among different HIV-1 strains (HIV DATABASES, http://www.hiv.
lanl.gov/content/index), as it serves as a key residue for CD4-
binding (Fig. 1D). Indeed, we found that the G367E mutation alone
causes a 10-fold decrease in the infectivity of HIV-1 particles.
Interestingly, this defect does not apparently affect the replication
of the EnvG367E mutant in SupT1 cells, and Vpu34 and EnvG367E
together enhance the viral growth in SupT1 cells as compared to
the wild type virus. How can HIV-1 tolerate such a deleterious
mutation as EnvG367E? One possibility is that SupT1 cells express
relatively high level of CD4 (Fig. 7B), which could support the
EnvG367E mutant to efﬁciently transmit from cell to cell (Fig. 6). In
addition, given that EnvG367E is unable to replicate in T cell lines
other than SupT1, SupT1 cells may express a factor(s) that allow
the replication of EnvG367E mutant.
We found that the Vpu34 and EnvG367E mutations were
unable to overcome the defect in viral p24 expression caused by
IFITM1 (Fig. 4). Instead, they enhanced the HIV-1 transmission
between SupT1 cells by 4-fold, indicating that the enhanced
replication of these mutants in SupT1 cells are due to cell-to-cell
transmission. It is possible that such a gain in cell-to-cell
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transmission allows HIV-1 to evade different types of restrictions.
This Vpu34/EnvG367E-dependent pattern requires SupT1 as the
target cells (Fig. 8), which suggests that certain features of the
infected target cells promote the formation of virological synapse.
These features may include high CD4 level at cell surface as a
result of losing Vpu and high level of the EnvG367E envelope that
has a weak afﬁnity for CD4 and therefore is less likely trapped at
the ER as a result of CD4 binding. Alternatively, the Vpu34/
EnvG367E mutant may be efﬁcient in entry via cell-associated
routes. It is currently unclear which of these possibilities promotes
HIV-1 cell-to-cell transmission. It is interesting to note that a
previous study by Gummuluru and colleagues has reported a Vpu
mutation called Rap5, which is very similar to Vpu34 (Gummuluru
et al., 2000). Rap5 was selected in a rapid turnover assay
performed in Jurkat cells, resulting in a frameshift of Vpu and
leading to the expression of its ﬁrst 32 amino acids, which is
remarkably similar to the Vpu34 mutation reported here. Impor-
tantly, Rap5 also rescued HIV-1 replication by promoting cell-to-
cell spread of virus, which is related to accumulation of Rap5
viruses on the cell surface, despite that Rap5 had no apparent
effect on the expression of Env. This mechanism was further
supported by a later study showing that, in the absence of Vpu,
tetherin promotes HIV-1 cell to cell transmission (Jolly et al., 2010).
Although this virus particle retention mechanism may not operate
for Vpu34 in SupT1 cells that do not express tetherin, the virus
manages to evolve a second mutation G367E in envelope protein
that, together with Vpu34, achieves higher transmission efﬁciency
to escape IFITM1 inhibition. Apart from enhanced cell-to-cell
transmission, we also observed that the EnvG367E virus caused
a delayed cytopathogenecity during infection of SupT1 cells as
compared to the wild type virus (data not shown), suggesting that
the attenuated binding of EnvG367E to CD4 likely also diminishes
cell fusion/killing and thereby allows the infected cells to produce
more viruses.
IFITM1 has been shown to inhibit entry of a number of
enveloped viruses, including IAV, Yellow Fever virus, SARS
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coronavirus, Ebola virus, etc. (Brass et al., 2009; Feeley et al., 2011;
Huang et al., 2011; Li et al., 2013). Interestingly, it does not appear
to restrict HIV-1 by impeding entry (Lu et al., 2011). Instead,
IFITM1 reduces HIV-1 Gag/p24 expression in virus producer cells,
which results in diminished virus production. Interestingly, we
found no evidence that the escape mutations would overcome this
latter defect. While it is possible that the effect of IFITM1 on HIV-1
is cell type speciﬁc and virus-strain dependent (Brass et al., 2009),
the identiﬁcation of the escape mutations that promote HIV-1 cell-
to-cell transmission, as reported here, demonstrates that HIV-1
can evolve a mechanism to evade IFITM1 restriction. We envision
that similar mechanisms are also operative for other viruses that
are restricted by IFITMs.
Conclusions
Our results demonstrate that HIV-1 is able to circumvent the
inhibition by IFITM1 in tissue culture by acquiring mutations in
viral Vpu and Env proteins. These mutations, namely Vpu34 and
G367E, do not seem to overcome the Gag downregulation caused
by IFITM1, but rather enable the virus to regain efﬁcient replica-
tion by promoting virus spread between cells.
Materials and methods
Plasmids and antibodies
The tetracycline-inducible IFITM1 SupT1 cell line was generated
as previously described (Lu et al., 2011). The HIV-1 BH10 proviral
DNA clone was obtained from the NIH AIDS Reference and Reagent
Program. The mutations Vpu34, EnvR311K, EnvG367E and g7178a
were engineered using the site-directed mutagenesis kit (Strata-
gene). The anti-Flag and anti-β actin antibodies were purchased
from Sigma, anti-tubulin antibody from Santa Cruz biotechnology,
anti-HIV-1 p24 antibody from ID Lab Inc., phycoerythrin (PE)-
conjugated anti-human CD4 antibody from BD Biosciences,
Dylight-649-conjugated anti-Flag antibody from Rockland, FITC-
Fig. 8. Cell-to-cell transmission of the HIV-1 wild type and mutants between different pairs of donor and target cells. (A) Transmission of the wild type and mutated HIV-1
between CEM cells. (B) HIV-1 transmission from SupT1 to CEM cells. (C) HIV-1 transmission from CEM to SupT1 cells. (D) Results of three independent transmission
experiments are summarized in the bar graph. The transmission efﬁciency of wild type HIV-1 is arbitrarily set as 1.
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conjugated anti-HIV-p24 antibody from Beckman. G418 was pur-
chased from Invitrogen, puromycin and doxycycline from Sigma.
Virus infection
HIV-1 stocks were produced by transfection of the human
embryonic kidney cell line (HEK293T) with HIV-1 proviral DNA.
The culture supernatants were clariﬁed by passing through the
0.2 mm ﬁlter (VWR) to remove the cell debris. Amounts of viruses
were determined by measuring viral p24 (CA) levels using the
HIV-1 p24 Antigen Capture Assay kit (Cat. 5447, ABL Inc.).
Virus infection was measured by four assays. First, infection of the
TZM-bl indicator cells that express CD4/CXCR4/CCR5 and contain the
HIV-1 LTR-Luc reporter (Wei et al., 2002). TZM-bl cells were ﬁrst
seeded into 24-well plates (4104 cells/well) one day before virus
infection. Forty hours after infection, cells were lysed with 1 passive
lysis buffer (Promega) and the levels of luciferase activity were
measured using the luciferase assay kit (Promega). Second, short-
term infection of the SupT1 cells. SupT1 cells were ﬁrst exposed to
viruses equivalent to 200 ng viral p24 antigen. Forty hours after
infection, the infected cells were washed with cold 1 phosphate-
buffered saline and ﬁxed with 1% paraformaldehyde. The infected cells
were stained with anti-HIV-1 p24 antibody and scored by ﬂow
cytometry. Third, long-term infection of SupT1 cells. SupT1 cells were
infected with virus equivalent to 10 ng viral p24. Viral replication was
monitored by measuring the levels of viral reverse transcriptase
activity in supernatants over various time intervals. Lastly, we used
the CEM-Rev-Luc cells to examine the sensitivity of HIV-1 to inhibition
by different agents. The CEM-Rev-Luc cells express luciferase in a
qHIV-1 Rev-dependent manner (Wu et al., 2007). These cells are a gift
of Dr. Yuntao Wu (George Mason University). Cells were ﬁrst pre-
treated for 1 hwith different doses of each of the ﬁve agents, including
soluble CD4 (sCD4), broadly neutralizing antibody VRC03, anti-CD4
antibody (SIM4), CXCR4 antagonist (AMD3100) and CCR5 antagonist
maraviroc (all agents were obtained from the NIH AIDS Reference and
Reagent Program). The cells were then infected with the same
amounts of different HIV-1 stocks. Forty hours after infection, cells
were lysed and luciferase activity was measured to determine virus
infection.
Identiﬁcation and cloning of the escape viruses
We started by infecting IFITM1-expressing SupT1 cells with
HIV-1 to monitor the development of resistant viruses. When
marked cytopathogenic effect and high levels of viral RT activity in
the supernatant were detected 3 weeks after infection, we used
these newly produced viruses to infect fresh IFITM1-expressing
SupT1 cells. After ﬁve such passages, HIV-1 was able to reach peak
level of its replication at 6–8 days instead of 20 days as observed in
the initial round of infection. We harvested SupT1 cells that were
infected by the highly replicable HIV-1 and extracted the total
cellular DNA using the DNeasy Blood & Tissue kit (Qiagen). Viral
genomic DNA was ampliﬁed with three primer pairs to cover the
entire genome. The PCR products were cloned into the PCR-Blunt
II-TOPO vector with Zero Blunt TOPO PCR Cloning Kit (Invitrogen).
An average of seven positive DNA clones for each PCR reaction was
sent to McGill University and Quebec Innovation Center for
sequencing. We also grew HIV-1 in the control SupT1 cells that
do not express IFITM1 for the same period of time, and viral
genomes were similarly ampliﬁed by PCR, cloned, and sequenced.
shRNA knockdown of CD4 in SupT1 cells
We purchased four shRNA clones that target human CD4 mRNA
(Sigma-Aldrich, catalog no. SHCLNG-NM_000616). The sequences
of these four shRNA are:
shRNA1-CCGGCCAGATAAAGATTCTGGGAAACTCGAGTTTCCCA-
GAATCTTTA TCTGGTTTTTG,
shRNA2-CCGGCCTTCTTAACTAAAGGTCCATCTCGAGATG GACCTT-
TAGTTAA GAAGGTTTTTG,
shRNA3-CCGGCCTGATCATCAAGAATCTTA ACTCGAGTTAAGATTC-
TTGATGA TCAGGTTTTTG, and
shRNA4-CCGGAGAGCGGATG TCTCAGATCAACTCGAGTTGATCT-
GAGACATC CGCTCTTTTTTG.
These shRNA clones were transfected into HEK293T cells together
with plasmid DNA pLP1 (encoding HIV-1 Gag and Gag-Pol), pLP2
(encoding HIV-1 rev) and pVSV-G (encoding VSV G protein) to
produce VSV-G pseudotyped lentiviral particles that package the
shRNA. SupT1 cells were then infected with these virus particles and
subject to selection with 2 mg/ml puromycin for stably transduced
cells. The empty shRNA vector was used to generate the control cell
line. The total amounts of CD4 in these SupT1 cell lines were
determined by Western blotting. To determine the cell surface level
of CD4, cells were ﬁrst incubated with the PE-conjugated anti-human
CD4 antibody on ice for 30 min, then ﬁxed with 1% paraformalde-
hyde. The positively stained cells were scored by ﬂow cytometry.
Only shRNA3 signiﬁcantly decreased CD4 level.
HIV-1 virion fusion assay
The experiment was performed as described previously
(Cavrois et al., 2002; Lu et al., 2011). Brieﬂy, 3 μg of HIV-1 DNA
was co-transfected with 1 μg pCMV-BlaM-Vpr DNA into 293T cells.
Supernatants containing virions were ﬁltered with 0.22 μm ﬁlter
and then concentrated by ultracentrifugation at 100,000g for 1 h
at 4 1C. Pelleted viruses were suspended with DMEM, quantiﬁed
for viral RT activity, aliquoted and stored at 80 1C. For virion
fusion assay, SupT1 cells were infected with the same amounts of
wild type HIV-1 and mutant viruses by spinoculation for 45 min at
room temperature, followed by incubation for 2 h at 37 1C. Cells
were then washed with CO2-independent medium (Invitrogen),
mixed with 100 μl loading solution (CCF2/AM substrate, Invitro-
gen) for 1 h at room temperature in the dark. After washing off the
loading solution, cells were incubated in 200 μl of development
medium in dark for 16 h at room temperature. Cells were washed
and ﬁxed with 3.7% formaldehyde. The cleavage of CCF2/AM was
measured by ﬂow cytometry.
Western blotting
Cell lysates were separated in 1% sodium dodecyl sulfate-12%
polyacrylamide gels (SDS-PAGE) by electrophoresis and then
transferred onto polyvinylidene diﬂuoride (PVDF) membranes
(Roche). The membranes were blocked with 4% skim milk (in
1 phosphate-buffered saline) and further probed with anti-p24
(1:5000), anti-β actin (1:5000) or anti-tubulin (1:5000) antibodies.
After a further incubation with horseradish peroxidase (HRP)-
conjugated secondary antibodies (GE Healthcare), the protein
bands were visualized by exposure to X-ray ﬁlms following a brief
treatment of the membranes with the ECL (enhanced chemilumi-
nescence) reagents.
Cell-to-cell transmission assay
SupT1 cells were ﬁrst infected with HIV-1 particles bearing
VSV-G protein. VSV-G protein was used to effectively increase the
infection rate of donor cells; however, the subsequent virus
transmission from donor cells to target cells was mediated by
HIV-1 Env. Forty hours after, the infected cells (designated as
donor cells) were washed with complete medium prior to mixing
S. Ding et al. / Virology 454-455 (2014) 11–2422
with un-infected SupT1 cells (designated as target cells) that had
been labeled with cell tracker BMQC (Invitrogen). After 8 h, the
cell mixtures were ﬁxed with 1% paraformaldehyde and permea-
lized with 0.1% Triton X-100. After staining with FITC-conjugated
anti-HIV-1 p24 antibody, the p24-positive donor and target cells
were scored by ﬂow cytometry. In order to control for the infection
by free HIV-1 particles, infections were also set up with trans-
wells that separated the donor from target cells but allowed the
free movement of HIV-1 particles. In addition, we performed
control experiments by adding the HIV-1 fusion inhibitor T-20
(2 mM, obtained from the NIH AIDS Reference and Reagent
Program) to the mixed donor and target cells in order to block
HIV-1 envelope-dependent cell-to-cell fusion.
HIV-1 transmission between cells was also determined by
measuring the production of viral late cDNA as described by Jolly
et al., (2010). Brieﬂy, the donor and target SupT1 cells were
collected at time 0 (before mixing) and 8 h after mixing. Total
cellular DNA was prepared using the DNeasy Blood & Tissue kit
(Qiagen). The same amounts of DNA from different infection
samples were subjected to real-time PCR to quantify HIV-1 late
DNA and cellular GAPDH DNA as described in (Lu et al., 2011). The
amounts of GAPDH DNA serve as internal controls.
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